Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Moonlake Immunotherapeutics (MLTX)

Moonlake Immunotherapeutics (MLTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 890,884
  • Shares Outstanding, K 64,231
  • Annual Sales, $ 0 K
  • Annual Income, $ -118,940 K
  • EBIT $ -229 M
  • EBITDA $ -228 M
  • 60-Month Beta 1.21
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 3.03

Options Overview Details

View History
  • Implied Volatility 134.40% (+8.13%)
  • Historical Volatility 66.18%
  • IV Percentile 87%
  • IV Rank 46.38%
  • IV High 238.49% on 09/17/25
  • IV Low 44.37% on 06/30/25
  • Expected Move (DTE 21) 2.98 (21.45%)
  • Put/Call Vol Ratio 0.04
  • Today's Volume 899
  • Volume Avg (30-Day) 4,344
  • Put/Call OI Ratio 0.18
  • Today's Open Interest 72,007
  • Open Int (30-Day) 77,916
  • Expected Range 10.90 to 16.85

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 18 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.97
  • Number of Estimates 7
  • High Estimate -0.73
  • Low Estimate -1.14
  • Prior Year -0.72
  • Growth Rate Est. (year over year) -34.72%

Price Performance

See More
Period Period Low Period High Performance
1-Month
12.48 +11.65%
on 12/02/25
15.56 -10.43%
on 12/08/25
+0.13 (+0.97%)
since 11/26/25
3-Month
5.95 +134.17%
on 09/29/25
15.56 -10.43%
on 12/08/25
-48.06 (-77.52%)
since 09/26/25
52-Week
5.95 +134.17%
on 09/29/25
62.75 -77.80%
on 09/26/25
-40.47 (-74.39%)
since 12/26/24

Most Recent Stories

More News
MLTX DEADLINE ALERT: Hagens Berman Alerts MoonLake (MLTX) Investors to Today's Lead Plaintiff Deadline in Securities Class Action

SAN FRANCISCO , Dec. 15, 2025 /PRNewswire/ -- Global plaintiffs' rights firm Hagens Berman reminds investors that the Lead Plaintiff Deadline in the securities class action lawsuit against ...

MLTX : 13.93 (+0.46%)
MoonLake Immunotherapeutics Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – MLTX

The DJS Law Group reminds investors of a class action lawsuit against MoonLake Immunotherapeutics (“MoonLake” or “the Company”) (NASDAQ: MLTX ) for violations of §§10(b)...

MLTX : 13.93 (+0.46%)
FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of MoonLake Immunotherapeutics

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In MoonLake To Contact Him Directly To Discuss Their...

MLTX : 13.93 (+0.46%)
Shareholders that lost money on MoonLake Immunotherapeutics(MLTX) Urged to Join Class Action - Contact The Gross Law Firm to Learn More

NEW YORK , Dec. 15, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of MoonLake Immunotherapeutics (NASDAQ: MLTX). 

MLTX : 13.93 (+0.46%)
MLTX Investors Have Opportunity to Lead MoonLake Immunotherapeutics Securities Fraud Lawsuit with the Schall Law Firm

The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against MoonLake Immunotherapeutics (“MoonLake” or “the Company”) (NASDAQ:...

MLTX : 13.93 (+0.46%)
MoonLake Immunotherapeutics Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - MLTX

LOS ANGELES , Dec. 15, 2025 /PRNewswire/ -- The DJS Law Group  reminds investors of a class action lawsuit against  MoonLake Immunotherapeutics ("MoonLake " or "the Company") (NASDAQ: MLTX...

MLTX : 13.93 (+0.46%)
MLTX Investors Have Opportunity to Lead MoonLake Immunotherapeutics Securities Fraud Lawsuit with the Schall Law Firm

LOS ANGELES , Dec. 15, 2025 /PRNewswire/ -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against MoonLake Immunotherapeutics...

MLTX : 13.93 (+0.46%)
Deadline Soon: MoonLake Immunotherapeutics (MLTX) Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit

The Law Offices of Frank R. Cruz reminds investors of the upcoming December 15, 2025 deadline to participate as a lead plaintiff in the securities fraud class action lawsuit filed...

MLTX : 13.93 (+0.46%)
MLTX Deadline: MLTX Investors with Losses in Excess of $100K Have Opportunity to Lead MoonLake Immunotherapeutics Securities Fraud Lawsuit

NEW YORK , Dec. 12, 2025 /PRNewswire/ --

MLTX : 13.93 (+0.46%)
MLTX Investor Deadline Alert: MoonLake (MLTX) Class Action Lawsuit - Hagens Berman Scrutinizing Nanobody Superiority Claims After 90% Plunge; December Lead Plaintiff Deadline Looms

SAN FRANCISCO , Dec. 12, 2025 /PRNewswire/ -- Global plaintiffs' rights firm Hagens Berman reminds investors that the Lead Plaintiff Deadline in the securities class action lawsuit against ...

MLTX : 13.93 (+0.46%)

Business Summary

MoonLake Immunotherapeutics AG is a clinical-stage biotechnology company. It focused on creating next-level therapies for inflammatory skin and joint diseases. MoonLake Immunotherapeutics AG, formerly known as Helix Acquisition Corp., is based in BOSTON.

See More

Key Turning Points

3rd Resistance Point 14.64
2nd Resistance Point 14.38
1st Resistance Point 14.12
Last Price 13.93
1st Support Level 13.61
2nd Support Level 13.35
3rd Support Level 13.10

See More

52-Week High 62.75
Fibonacci 61.8% 41.05
Fibonacci 50% 34.35
Fibonacci 38.2% 27.65
Last Price 13.93
52-Week Low 5.95

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar